Vivos Therapeutics Expands Reach with New Acquisition in Sleep Care
Vivos Therapeutics, Inc. (NASDAQ: VVOS) is taking significant strides in its mission to enhance sleep wellness by acquiring The Sleep Center of Nevada (SCN), a prominent medical sleep center in Nevada. This strategic acquisition is set to substantially increase Vivos' OSA diagnostic revenue while expanding its innovative non-invasive treatment options to a broader patient demographic.
The acquisition marks a pivotal milestone in Vivos’ shifting business model, steering focus from traditional dental affiliations to high-volume medical practices. With this strategic move, Vivos aims to serve patients more effectively by integrating its highly regarded therapy options with SCN’s established patient base.
Unlocking New Revenue Streams with SCN
SCN has established itself as a leader in treating sleep disorders like obstructive sleep apnea (OSA), insomnia, and restless leg syndrome. The center sees approximately 3,000 new patients each month, generating substantial annual revenues. The incorporation of Vivos’ patented treatments will not only diversify Vivos' service offerings but also enable immediate revenue capture from both OSA diagnostics and consultations. This promises to boost the financial health of Vivos while catering to the growing market of patients dissatisfied with the conventional CPAP treatments.
Revolutionizing Treatment Approaches
Historically, many patients at SCN have been referred to less effective treatments such as CPAP machines or surgical procedures. However, with Vivos’ advanced oral appliance solutions, which have received FDA clearance, the company is poised to create a compelling alternative for these patients. This shift presents a remarkable opportunity to re-engage those who have sought other methods of care.
Building a Robust Operational Framework
As Vivos integrates SCN into its operations, it has already demonstrated a proactive approach by equipping and staffing multiple locations to manage patient flow effectively. This groundwork paves the way for a smoother transition and ensures continuous care is provided from day one.
Strategic Financial Moves for Growth
To finance this acquisition, Vivos has secured over $11 million in funding. This includes a senior secured term loan from Streeterville Capital LLC and a private placement investment from New Seneca Partners, a significant private equity investor in Vivos. These funds are crucial for the successful implementation and operation of SCN’s integration and will provide needed capital for future growth ventures.
Vivos’ Chairman and CEO, Kirk Huntsman, expressed enthusiasm about this acquisition, highlighting the immediate booking of SCN’s patients and strong demand for more effective sleep disorder treatments. The excitement around the acquisition is not only internal; it resonates through the SCN team, particularly among Dr. Prabhu Rachakonda and Dr. Tara Rachakonda, both of whom are committed to bringing Vivos' award-winning treatments to their practice.
Looking Ahead: Expansion and Future Initiatives
The acquisition culminates Vivos’ strategic pivot toward collaborating with medical sleep practices, positioning the company for potential expansions beyond 2025. With a solid foundation at SCN, Vivos is now looking to identify further opportunities for collaboration or acquisition, enhancing its market position in the sleep medicine landscape.
Vivos’ Commitment to Sleep Wellness
With a focus on innovation, Vivos Therapeutics seeks to address the critical need for expanded access to various treatment modalities for OSA. The challenges faced by many individuals suffering from sleep disorders are substantial, and Vivos aims to rectify this by providing comprehensive solutions that ensure a better quality of life for its patients.
As Vivos embarks on this new chapter, the company remains committed to refining and expanding its treatment approaches, leveraging its strengths in research and innovation to foster improved health outcomes for those in need.
Frequently Asked Questions
What is the main purpose of Vivos' acquisition of SCN?
Vivos aims to enhance its revenue from OSA diagnostics and treatments by integrating with SCN's established medical practice and patient base.
How does Vivos’ treatment differ from conventional OSA therapies?
Vivos offers non-invasive oral appliance solutions that are FDA-cleared, providing alternatives to traditional CPAP methods.
What financial strategies did Vivos employ for this acquisition?
Vivos secured over $11 million in financing through a mix of loans and equity investments to facilitate the acquisition and future expansions.
Who are the key individuals involved in the transitions at SCN?
Dr. Prabhu Rachakonda and Dr. Tara Rachakonda are pivotal figures from SCN, joining Vivos to continue managing their practice post-acquisition.
What does the future hold for Vivos following this acquisition?
Vivos intends to pursue more collaborations and acquisitions in the sleep medicine sector, enhancing its market presence and treatment offerings.
